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Abstract
Background: The neurotrophin BDNF has been implicated in the regulation of neuroplasticity,
gene expression, and synaptic function in the adult brain, as well as in the pathophysiology of
neuropsychiatric disorders and the mechanism of action of antidepressants. Antidepressant
treatments have been shown to increase the expression of BDNF mRNA, although the changes
measured were found to be different depending on various factors. A few studies only have
measured levels of BDNF protein after antidepressant treatments, and poor correlation was found
between mRNA and protein changes. We studied the time course of expression of BDNF mRNA
and protein during drug treatments, in order to elucidate the temporal profile of regulation of this
effector and whether mRNA and protein levels correlate. Rat groups were treated for 1, 2 or 3
weeks with fluoxetine or reboxetine; in additional groups drug treatment was followed by a
washout week (3+1). Total BDNF mRNA was measured by Real Time PCR, pro- and mature
BDNF proteins were measured by Western blot.
Results: We found that mature BDNF protein is induced more rapidly than mRNA, by both drugs
in hippocampus (weeks 1–2) and by reboxetine in prefrontal/frontal cortex (week 1). The temporal
profile of BDNF protein expression was largely inconsistent with that of mRNA, which followed
the protein induction and reached a peak at week 3.
Conclusion:  These results suggest that BDNF protein is rapidly elevated by antidepressant
treatments by posttranscriptional mechanisms, and that induction of BDNF mRNA is a slower
process.
Background
Brain-Derived Neurotrophic Factor (BDNF) is an abun-
dant neurotrophin regulating neuroplasticity, gene
expression, synaptic function and cognition in the adult
brain [1,2], that has been implicated in the pathophysiol-
ogy of various neuropsychiatric and neurodegenerative
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disorders as well as in the mechanism of action of antide-
pressant drugs [3-9]. It is generally assumed that antide-
pressant treatments increase the expression of BDNF,
which, according to the neurotrophic hypothesis, repre-
sents an effector of changes in neuroplasticity and cellular
resilience mediating the long-term therapeutic effect of
antidepressants. In this framework BDNF has lately
become, together with the activation of cAMP-response
element binding protein (CREB), a sort of readout system
in the study of antidepressant mechanisms [4,5,7,8,10-
14].
However, several studies have shown that the changes in
the expression of BDNF can be quite different depending
on various factors, such as type of drug, dosage, route of
administration, length of treatment (see ref. [9] for discus-
sion). Moreover, only a few studies have measured levels
of BDNF protein after antidepressant treatments [10,15-
19] and, when mRNA and protein levels have been meas-
ured at the same time, poor correlation was found
between mRNA and protein changes [16,17]. In addition,
the rat BDNF gene has a complex structure with at least
eight 5' exons that can be spliced to a single 3' exon con-
taining the coding domain for the BDNF protein, generat-
ing 11 different transcripts according to the last
nomenclature [20]. This makes the effect of drug treat-
ments on BDNF expression more complex to explain,
because the changes in total BDNF can potentially be
related to changes in different non-coding exons spliced
to the coding exon (exon IX).
In this study, with regard to the action of antidepressants,
we asked the following questions:
1. What is the time course of BDNF expression during
antidepressant treatment? Is it consistent with the onset of
therapeutic effect?
2. What is the expression level of BDNF after1 week-wash-
out?
3. How does BDNF protein expression profile during
treatment correlate with BDNF mRNA expression?
In order to assess the time-course of BDNF expression dur-
ing long-term antidepressant treatments, we have treated
rats with two different drugs endowed with complemen-
tary mechanisms: fluoxetine (FLX), a selective serotonin
reuptake inhibitor (SSRI), and reboxetine (RBX), a selec-
tive norepinephrine reuptake inhibitor (NRI). The drug
treatments were carried out for 1, 2 or 3 weeks and were
followed by an additional washout week (3+1), that was
added in order to study the fate of BDNF expression when
antidepressant treatment is discontinued. In all these rat
groups we assessed the expression of total BDNF at both
mRNA and protein levels, measuring both the pro- and
mature forms of BDNF [1,21,22]. We found that mature
BDNF protein is induced in hippocampus more rapidly
than mRNA, suggesting that antidepressants rapidly regu-
late BDNF at posttranscriptional level.
Results
Distinct temporal profile of expression of total BDNF 
mRNA induced by fluoxetine and reboxetine
We measured the changes in BDNF expression induced by
the two drug treatments at the level of both mRNA and
protein, in HPC and P/FC. Total BDNF mRNA was
detected by means of quantitative Real Time PCR, using
primers designed on the sequence of the coding exon
(exon IX). 2-Way ANOVA showed in HPC an effect of
time (F4,79 = 147.31; p < 0.0001), drug (F1,79 = 37.31; p <
0.0001) and time/drug interaction (F4,79 = 24.61; p <
0.0001). Similarly, in P/FC there was an effect of time
(F4,50 = 44.24; p < 0.0001), drug (F1,50 = 4.38; p < 0.0001)
and time-drug interaction (F4,50 = 3.80; p < 0.01). As
shown in Fig. 1A–B, the temporal profile of activation of
mRNA expression by FLX and RBX was similar in the two
brain areas, but typical of either drug. The levels of total
BDNF mRNA were induced starting with week 1 (RBX) or
2 (FLX) and peaked at week 3 with both drugs (particu-
larly with FLX). During the washout week the mRNA level
was sharply reduced for FLX, although maintaining a sig-
nificantly higher than basal level. This gap between week
3 and 3+1 was less pronounced for RBX, for which the
mRNA level at week 3+1 was also significantly higher than
basal level.
Expression profile of BDNF protein induced by fluoxetine 
and reboxetine consistent with early translation of mRNA
The expression of the BDNF protein follows a multi-step
process of maturation from a pre-propeptide through a
proprotein to the mature form of BDNF [21]. We meas-
ured by Western blot both the 32 kDa pro-BDNF and 14
kDa mature BDNF, the two most abundant forms of the
protein [1,5], in the total extract of HPC and P/FC at the
different treatment times as above (Fig. 2). The two drugs
showed different effects on BDNF protein levels in the two
areas. In HPC (Fig. 2A–C), 2-Way ANOVA showed an
effect of time and drug for both pro-BDNF (F4,59 = 26.71;
p < 0.0001; F1,59 = 24.16; p < 0.0001) and mature BDNF
(F4,89 = 12.17; p < 0.0001; F1,89 = 65.08; p < 0.0001) and
of time/drug interaction for pro-BDNF (F4,59 = 4.65; p <
0.01). In HPC, FLX induced a trend toward increase of
pro-BDNF at weeks 1–2, which became significant at week
3, while RBX up-regulated pro-BDNF at weeks 2–3. Both
FLX and RBX consistently up-regulated the expression of
mature BDNF at all times in HPC, with maximum at
weeks 2–3 for FLX and 1 to 3 for RBX (Fig. 2A–C).
In P/FC (Fig. 2B–D), 2-Way ANOVA showed an effect of
time (F4,53 = 7.69; p < 0.0001) and time/drug interaction
(F4,53 = 4.07; p < 0.01) for pro-BDNF and an effect of timeBMC Neuroscience 2009, 10:48 http://www.biomedcentral.com/1471-2202/10/48
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(F4,54 = 44.79; p < 0.0001) and drug (F1,54 = 12.53; p <
0.001) for mature BDNF. Indeed, both FLX and RBX up-
regulated pro-BDNF, with the only exception of week 3
for FLX. Differently from the HPC, in P/FC the up-regula-
tion of pro-BDNF by FLX sharply contrasted with the
absence of changes in mature BDNF (Fig. 2B–D). As in
HPC, RBX consistently up-regulated mature BDNF at all
times.
Overall, the regulation of mRNA and protein was not con-
sistent in HPC and P/FC for both drugs. No mature BDNF
was induced by FLX in P/FC. The results showed that in
HPC the level of mature BDNF protein reached a peak
(weeks 1–2) before the actual peak of mRNA (week 3),
suggesting early translation and processing of the protein
during antidepressant treatment. The same was observed
for RBX in P/FC.
Discussion
The main findings of this work were that BDNF mRNA
and protein levels during antidepressant treatments did
not correlate, and that induction of mature protein pre-
ceded that of mRNA. The measurement of BDNF mRNA
expression showed an overall similar temporal profile of
induction with the two drugs. RBX acted somewhat faster,
inducing BDNF mRNA already at week 1 in both areas,
while FLX induced BDNF from week 2. The shape of this
induction was also somewhat different; FLX progressively
increased the expression up to week 3, while RBX induced
BDNF in two distinct waves. After a precocious induction
at week 1, the expression of BDNF was not further
increased (P/FC) or was reduced (HPC) by RBX between
week 1 and 2. A second, more pronounced, wave of BDNF
induction by RBX was observed between week 2 and 3.
Overall, RBX acted faster on BDNF transcription but FLX
outsized RBX with regard to the maximum extent of
mRNA induction. Interestingly, the washout week also
differently affected the outcome of the two drug treat-
ments in HPC, because it sharply reduced the effect of FLX
in both areas and of RBX in P/FC, while in HPC of RBX-
treated rats BDNF mRNA level was unchanged at week
3+1. In a companion study [23], we previously found that
1 washout week entirely abolished the activation of CREB
induced by 3 weeks of RBX, but not of FLX, in line with
the longer half-life of norFLX, the active FLX metabolite.
This discrepancy between the effects of washout on activa-
tion of CREB vs. BDNF expression may underscore the
complex regulation of the BDNF gene, that contains sev-
eral different regulatory elements (other than CRE) at the
level of promoters [24].
Surprisingly, the temporal profile of BDNF protein expres-
sion in HPC was largely inconsistent with that of mRNA
expression (compare Fig. 1A with Fig. 2C). Although with
FLX a significant increase of mRNA was not observed until
week 2, in the same rats mature BDNF (14 kDa) was
already significantly elevated at week 1 and reached max-
imal level at week 2, when mRNA level was still far below
Time course of expression levels of BDNF total mRNA following antidepressant treatment Figure 1
Time course of expression levels of BDNF total mRNA following antidepressant treatment. Expression levels of 
BDNF total mRNA in HPC (A) and P/FC (B) of rats treated with FLX and RBX. Data are expressed as % of controls (mean ± 
s.e.m.). Bonferroni post-hoc test: FLX-treated vs. control rats: ** p < 0.01, *** p < 0.001; RBX-treated vs. control rats: § p < 
0.05, §§ p < 0.01, §§§ p < 0.001.BMC Neuroscience 2009, 10:48 http://www.biomedcentral.com/1471-2202/10/48
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Time course of expression levels of BDNF protein following antidepressant treatment Figure 2
Time course of expression levels of BDNF protein following antidepressant treatment. Time course of expression 
levels of BDNF protein precursor of 32 kDa (A, B) and mature protein of 14 kDa (C, D) in HPC (A, C) and P/FC (B, D) of rats 
treated with FLX or RBX. Insets: representative immunoreactive bands from Western blots. Data and statistic analysis as 
above. FLX-treated vs. control rats: * p < 0.05, ** p < 0.01, *** p < 0.001; RBX-treated vs. control rats: § p < 0.05, §§ p < 0.01, 
§§§ p < 0.001.BMC Neuroscience 2009, 10:48 http://www.biomedcentral.com/1471-2202/10/48
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the maximal level attained at week 3. Instead, the level of
pro-BDNF (32 kDa) in HPC was significantly elevated
only at week 3. A possible explanation for this discrepancy
is that, in the first several days of FLX treatment, BDNF
mRNA already available is rapidly translated and the
proBDNF produced is also rapidly processed to mature
BDNF, suggesting that FLX has a more rapid effect on
BDNF translation/processing than on the transcription of
BDNF gene. Although more in line with the early induc-
tion of mRNA by RBX, the profile of induction of mature
BDNF by this second drug was also inconsistent with the
profile of mRNA induction, which reached maximal level
only at week 3 (as for FLX). With RBX the level of mature
BDNF was already maximal at week 1 and remained
steadily elevated up to week 3, suggesting again a rapid
effect of the drug on BDNF translation/processing, per-
haps accelerated by the induction of new mRNA at week
1 by RBX.
In P/FC the effects of the two drugs on BDNF translation
were different from each other. Maximal level of mature
BDNF was induced by RBX already at week 1, as in the
HPC, although the extent of increase was somewhat
smaller than in HPC. Again, the temporal profile of the
protein was inconsistent with that of mRNA, which
reached maximal level only at week 3. By contrast, no
mature BDNF was detected at any time point during FLX
treatment, although moderate levels of proBDNF were
attained, suggesting that in P/FC FLX was able to induce
transcription of BDNF but little translation and no
processing of the protein. Previous studies did not find
induction of BDNF protein by FLX or other antidepres-
sants in frontal cortex [15,17]. This substantial lack of
induction of BDNF protein by FLX in P/FC would suggest
that downstream effects of this drug on synaptic plasticity
are more powerful in HPC than in prefrontal/frontal areas
of cerebral cortex.
The present results are in line with the several reports that
previously showed up-regulation of BDNF mRNA
induced by chronic antidepressant treatments, often
increasing with the length of treatment [16,25]. We also
found here, as in two previous studies [16,17], a lack of
correlation between mRNA and protein, to the point that
in HPC detectable levels of BDNF protein were raised
faster than those of mRNA by the drug treatment. Overall,
the differences in levels of BDNF protein we detected are
somewhat bigger than in previous studies using the same
drugs; this could be due to the fact that we measured here
for the first time BDNF levels in a time-course treatment
by Western analysis rather than by ELISA, a method that
does not allow to distinguish between pro- and mature
BDNF.
The present results would suggest that two antidepres-
sants, FLX and RBX, have a particularly fast effect on post-
transcriptional regulation of BDNF in HPC (RBX also in
P/FC). It has already been suggested that BDNF synthesis
could be regulated at posttranscriptional level [17], as
found for other proteins [26]. First, it is known that
selected BDNF transcripts are located at dendrites, a mech-
anism that allows rapid regulation of translational control
[27]; we recently found that in rats treated with FLX or
RBX more BDNF mRNA is located at dendrites in CA3
hippocampal area (Tongiorgi E, Popoli M; unpublished).
Second, it was recently suggested that microRNAs exert a
robust effect on BDNF levels in mature human prefrontal
cortex, participating in posttranscriptional fine tuning of
BDNF expression [28]. Third, it was recently shown that
cleavage of pro- to mature BDNF is regulated by neuronal
activity [22]; changing the processing of pro-BDNF by
proteolytic enzymes could be an additional way whereby
antidepressants rapidly increase the production of mature
BDNF. This could explain why in HPC we found a faster
rise of mature BDNF compared to pro-BDNF (compare
Fig. 2A with Fig. 2C). Investigation of these mechanisms
in subchronic and chronic treatments with antidepres-
sants is warranted.
Finally, the finding that BDNF, a major readout effector, is
rapidly elevated in HPC by antidepressant treatment may
suggest that later downstream events are required to elicit
systemic and behavioral effects of antidepressants. If
BDNF production is faster than thus far envisaged, per-
haps the correlates of the therapeutic effects should be
searched in the actual cellular/molecular changes induced
by the action of BDNF, such as the modifications in syn-
aptic plasticity and the increment of neurogenesis. Further
work is required to characterize these events.
Conclusion
The results of the present study show that BDNF protein is
rapidly elevated by antidepressant treatments whereas the
induction of BDNF mRNA is a slower process, suggesting
that posttranscriptional mechanisms are involved in the
mechanism of antidepressants.
Methods
Drug treatment and preparation of total extract
Experiments complied with guidelines for use of experi-
mental animals of European Community Council Direc-
tive 86/609/EEC. All efforts were made to minimize
animal distress and to reduce the numbers of animals
used in this study. Groups of 12 male Sprague-Dawley rats
(6 week-old at beginning of treatment) (Charles River
Calco, Italy) were treated with vehicle (water), FLX or RBX
at 10 mg/kg rat weight/day, delivered in drinking water;
the average water intake per day for each cage (two rats)
was recorded for 4 days before starting and throughoutBMC Neuroscience 2009, 10:48 http://www.biomedcentral.com/1471-2202/10/48
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the treatment, and the drug solutions were changed every
two days according to animals' weight, as reported in pre-
vious studies [29]. Rats were divided in 9 experimental
groups: control (water), 1 week-treatment (FLX or RBX), 2
week-treatment (FLX or RBX), 3 week-treatment (FLX or
RBX) and 3 week-treatment (FLX or RBX) plus 1 week
drug washout (Fig. 3). All the animals were sacrificed at
the same age. Hippocampus (HPC) and the whole frontal
lobe, referred to as prefrontal/frontal cortex (P/FC), were
quickly excised on ice as previously shown [30,31]. Each
hemi-HPC and -P/FC from right or left hemisphere was
taken separately and randomly assigned for RNA (frozen)
or protein analysis. For the latter, the tissue was freshly
homogenized 1:10 (w/v) in homogenization buffer (0.28
M sucrose, 10 mM HEPES pH 7.4, 0.1 mM EGTA, 20 mM
NaF, 5 mM Na2PO4, 1 mM Na2VO4, 2 ml/ml of protease
inhibitor cocktail (Sigma-Aldrich, St Louis, MO) to obtain
the total extract, that was aliquoted and stored at -80°C.
RNA isolation, cDNA synthesis and Real-time quantitative 
PCR
Total RNA was isolated with Trizol (Invitrogen, Carlsbad,
CA). 2 μg of RNA were reverse transcribed using Super-
Script™ II Reverse Transcriptase (Invitrogen) and 0.5 μg
random hexamers (Promega, Madison, WI) in a 50 μl
final volume. Real-time PCR was carried out using a Light-
Cycler rapid thermal cycler System (Roche Diagnostics,
Mannheim, Germany) and SYBR Green was used for the
detection of double-strand DNA. The PCR reaction was set
up into microcapillary tubes in a volume of 20 μl with 2
μl of cDNA and 2 μl of LightCycler DNA Master SYBR
Green I (Roche Diagnostics). For BDNF quantitation, fwd
AGCTGAGCGTGTGTGACAGT and rew ACCCATGGGAT-
TACACTTGG primers were used, while for β-actin quanti-
tation, used as internal control [32,33], fwd
GGGAAATCGTGCGTGACATT and rwd CGGATGT-
CAACGTCACACTT primers were used. The PCR program
included an initial denaturation step during 30 s at 95°C,
followed by 45 cycles of a 1 s melting step at 95°C, a 10 s
annealing step at 58°C, and a 10 s elongation step at 72°C
(all temperature transition rates were 20°C/s). At the end
of each cycle, the fluorescence emitted by SYBR Green was
measured. At the end of PCR reaction, samples were sub-
jected to a temperature ramp (from 70°C to 95°C, 2°C/s)
with continuous fluorescence monitoring for melting
curve analysis. For each PCR product, a single narrow peak
was obtained by melting curve analysis at the specific tem-
perature. Each sample was assayed in duplicate and the
analysis was performed with Light Cycler Relative Quanti-
fication Software. Samples containing no template were
used as negative controls in each experiment.
Western blot Analysis
Western blot analysis was carried out as described previ-
ously [34], by incubating PVDF membranes, containing
electrophoresed proteins from total homogenates, with
polyclonal antibodies for BDNF 1:500 (Santa Cruz Bio-
technologies, Santa Cruz, CA). A minimum of 2–3 repli-
cates per rat were carried out in the different treatment
groups (vehicle, FLX, RBX). Following incubation with
peroxidase-coupled secondary antibodies, protein bands
were detected by using ECL (GE Healthcare, Uppsala,
Sweden). Standard curves were obtained by loading
increasing amounts of samples on gels as described previ-
ously [34]. All protein bands used were within the linear
range of standard curves and normalized for β-actin level
in the same membrane. Standardization and quantitation
was as reported previously, except that Quantity One soft-
ware (BioRad Laboratories, Hercules, CA) was used.
Statistical Analysis
All data were analyzed by using two-way analysis of vari-
ance (2-Way ANOVA) for the variable treatment (FLX/
RBX) and the variable time (Cnt, 1 week, 2 weeks, 3
weeks, 3+1 washout week). If the analysis of variance
revealed significant group differences, post-hoc Bonfer-
roni tests were carried out to elucidate the pattern of group
differences. Significance was assumed at p < 0.05. Statisti-
cal analysis of the data was carried out using GraphPad
Prism 4 (GraphPad Software, Inc., San Diego, CA).
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